COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.
Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable:
- Faster doubling times – Reaching as low as 17 hours, which can significantly shorten processing timelines; 30% faster than industry standards
- Improved transfection efficiencies – Reducing the amount of DNA and transfection reagents required for production
- Increased titers – Supporting higher virus production at a lower cost
“The current industry standard for media-based cell line development — typically focused on a limited set of factors, such as glucose, glutamine, nitrogen and ammonia — can potentially limit scalability, which is mission critical when selecting cell lines during the early stages of cell and gene therapy development to stay competitive,” said Michael Stewart, Matica Bio’s chief technology officer. “As a specialized CDMO, we are changing the rules of the game by incorporating a more holistic, multi-dimensional philosophy into our cell line platforms for cell and gene therapies, which incorporates some of the most advanced processes, analytical technologies and media analysis available. This fine tuning is absolutely necessary to reduce bottlenecks for any viral vector expression system, which, in turn, can improve yields and enable doubling times that are faster than other cell line service offerings on the market.”
MatiMaxTM is available for customers to use today, and comes in four different cell line options:
- HEK293: Adherent
- HEK293: Suspension
- HEK293T: Adherent
- HEK293T: Suspension
“As advances in gene modified therapies continue to grow, Matica Bio is well-positioned to support the exploding number of cell and gene therapy candidates under development, which helps our clients reach the clinic faster with high-quality products,” said Andrew Arrage, Matica Bio’s Chief Commercial Officer. “We already have several clients currently using MatiMaxTM lines, which have immediate availability and attractive licensing terms. Our objective is to empower biopharmaceutical developers to achieve their clinical and commercial goals, and, ultimately, treat more patients.”
For more details about the new MatiMaxTM cell lines, visit www.maticabio.com.
About Matica Biotechnology, Inc.
Matica Biotechnology, Inc. (Matica Bio) is a contract development and manufacturing organization (CDMO) specializing in fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in College Station, Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions. Advance your therapy from idea to patient with the experts at Matica Bio. Visit www.maticabio.com.
